Quality of life (Patient Benefit Questionnaire, 10-point scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes quality of life (Patient Benefit Questionnaire, 10-point scale) compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF5 Dietary supplements vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated dietary supplement; 628 participants (12 RCTs); very low. Subgroups: ALA without…
12 studies · 628 participants
Very low
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · benzydamine hydrochloride
SoF9 Topical treatments vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated topical treatment; 150 participants (4 RCTs); very low. Subgroups: benzydamine (1…
4 studies · 150 participants
Very low
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
It is very uncertain whether vitamin A or retinoids (systemic or topical; incl. 13-cis-retinoic… changes oral cancer development compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes oral cancer development compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
2 findings from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes clinical resolution (oral lesion not completely resolved) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether electromagnetic radiation (low-level laser therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 3, Safety of the intervention over 3 months: systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects, 20 placebo participants reported 20; 4 grade 3 events; 2 discontinued. Ketorolac…
2 studies
GRADE not reported
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).
1 finding from 1 review